Treatment of LAG-3 positive tumors

Patent metadata

Field	Value
Publication number	US-12049503-B2
Application number	US-202318451990-A
Country	US
Kind code	B2
Filing date	Aug 18, 2023
Priority date	May 30, 2017
Publication date	Jul 30, 2024
Grant date	Jul 30, 2024

Abstract

The invention provides a method of treating a tumor in a human patient comprising (i) identifying a patient as having a LAG-3 positive tumor and (ii) administering to the patient a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor, or an anti-CTLA4 antibody. In some embodiments, the method further comprises identifying the patient as having a LAG-3 positive PD-L1 positive tumor. In some embodiments, the LAG-3 inhibitor is an anti-LAG-3 antibody and the PD-1 pathway inhibitor is an anti-PD-1 antibody. The methods of the invention can improve response rates to treatment with a PD-1 pathway inhibitor, a combination of a PD1 pathway inhibitor and an immune checkpoint inhibitor, or a combination of a LAG-3 inhibitor and a PD-1 pathway inhibitor.

First claim

What is claimed is:

1. A method of treating a malignant tumor in a human patient, comprising administering an immunotherapy to the patient, wherein the immunotherapy comprises (i) an anti-LAG-3 antibody or antigen-binding fragment thereof and (ii) an anti-PD-1 antibody or antigen-binding fragment thereof or an anti-PD-L1 antibody or antigen-binding fragment thereof, and wherein about 1% to about 5% of nucleated cells in a sample of the patient's tumor are tumor-infiltrating lymphocytes expressing LAG-3.

2. The method of claim 1 , further comprising determining the level of LAG-3 expression in the sample prior to administering the immunotherapy.

3. The method of claim 1 , wherein the sample of the patient's tumor is PD-L1 negative.

4. The method of claim 3 , further comprising determining the level of LAG-3 expression and PD-L1 expression in the sample prior to administering the immunotherapy.

5. The method of claim 1 , wherein the malignant tumor is a liver cancer, bone cancer, pancreatic cancer, skin cancer, oral cancer, cancer of the head or neck, breast cancer, lung cancer, cutaneous or intraocular malignant melanoma, renal cancer, uterine cancer, ovarian cancer, colorectal cancer, colon cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, cancers of the childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, environmentally induced cancers, hematologic malignancies, viral-related cancer, or a combination thereof.

6. The method of claim 1 , wherein the malignant tumor is a melanoma, small cell lung cancer, non-small cell lung cancer (NSCLC), human papilloma virus (HPV)-related tumor, gastric adenocarcinoma, multiple myeloma, B-cell lymphoma, Hodgkin lymphoma/primary mediastinal B-cell lymphoma, non-Hodgkin's lymphoma, acute myeloid lymphoma, chronic myelogenous leukemia, chronic lymphoid leukemia, follicular lymphoma, diffuse large B-cell lymphoma, Burkitt's lymphoma, immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, mantle cell lymphoma, acute lymphoblastic leukemia, mycosis fungoides, anaplastic large cell lymphoma, T-cell lymphoma, precursor T-lymphoblastic lymphoma, gastroesophageal junction cancer, head and neck squamous cell carcinoma, renal cell cancer, or hepatocellular carcinoma.

7. The method of claim 1 , wherein the malignant tumor is refractory to treatment with an immune checkpoint inhibitor.

8. The method of claim 1 , wherein the anti-PD-1 and anti-LAG-3 antibodies or antigen-binding fragments thereof are formulated together.

9. The method of claim 1 , wherein the anti-PD-1 and anti-LAG-3 antibodies or antigen-binding fragments thereof are formulated separately.

10. The method of claim 1 , wherein the anti-PD-1 antibody or antigen-binding fragment thereof is administered concurrently with the anti-LAG-3 antibody or antigen-binding fragment thereof.

11. The method of claim 1 , wherein the anti-LAG-3 antibody or antigen-binding fragment thereof and anti-PD-1 antibody or antigen-binding fragment thereof are administered as a first or second line of treatment.

12. The method of claim 1 , wherein the anti-LAG-3 antibody or antigen-binding fragment thereof comprises (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:7; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:8; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:9; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO: 10; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO: 11; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO: 12.

13. The method of claim 1 , wherein the anti-LAG-3 antibody or antigen-binding fragment thereof comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs:3 and 5, respectively.

14. The method of claim 1 , wherein the anti-LAG-3 antibody or antigen-binding fragment thereof comprises BMS-986016, MK-4280 (28G-10), REGN3767, IMP731 (H5L7BW), BAP050, IMP-701 (LAG-525), Sym022, TSR-033, MGD013, FS118, or GSK2831781, or an antigen-binding fragment thereof.

15. The method of claim 1 , wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:23; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:24; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:25; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:26; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:27; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:28.

16. The method of claim 1 , wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises heavy and light chain variable regions comprising the sequences set forth in SEQ ID NOs: 19 and 21, respectively.

17. The method of claim 1 , wherein the anti-PD-1 antibody or antigen-binding fragment thereof comprises pembrolizumab, pidilizumab, or nivolumab, or an antigen-binding fragment thereof.

18. The method of claim 1 , wherein the anti-PD-L1 antibody or antigen-binding fragment thereof comprises atezolizumab, durvalumab, avelumab, or BMS-936559, or an antigen-binding fragment thereof.

19. A method of treating a malignant tumor in a human patient, comprising administering an immunotherapy to the patient, wherein the immunotherapy comprises (i) an anti-LAG-3 antibody or antigen-binding fragment thereof and (ii) an anti-PD-1 antibody or antigen-binding fragment thereof or an anti-PD-L1 antibody or antigen-binding fragment thereof, and wherein about 1% to about 20% of nucleated cells in a sample of the patient's tumor are tumor-infiltrating lymphocytes expressing LAG-3.

20. The method of claim 19 , wherein the sample of the patient's tumor is PD-L1 negative.

21. The method of claim 19 , wherein about 1% to about 10% of nucleated cells in a sample of the patient's tumor are tumor-infiltrating lymphocytes expressing LAG-3.

22. The method of claim 19 , wherein the anti-LAG-3 antibody or antigen-binding fragment thereof comprises (a) a heavy chain variable region CDR1 comprising the sequence set forth in SEQ ID NO:7; (b) a heavy chain variable region CDR2 comprising the sequence set forth in SEQ ID NO:8; (c) a heavy chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:9; (d) a light chain variable region CDR1 comprising the sequence set forth in SEQ ID NO: 10; (e) a light chain variable region CDR2 comprising the sequence set forth in SEQ ID NO: 11; and (f) a light chain variable region CDR3 comprising the sequence set forth in SEQ ID NO:

Assignees

• Bristol Myers Squibb Co

Inventors

• Novotny James
• Lonberg Nils
• Hedvat Cyrus
• Clynes Raphael
• Locke Darren
• Cogswell John P
• Jackson Jeffrey
• Harbison Christopher
• Edwards Robin

Classifications

• G01N33/575 Primary

  for cancer · CPC title

• G01N33/5758 Primary

  involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites · CPC title

• G01N33/5751

  of the skin, e.g. melanoma · CPC title

• C07K2317/31

  multispecific · CPC title

• C07K16/2803

  against the immunoglobulin superfamily · CPC title